Redefining the Limits in the Field of Cytokine Signaling Inhibitors

A new strategy for medicinal discovery to precisely control key pathways in auto-immune and chronic inflammatory diseases, including neuro-inflammation.

Precise immune control. Broad therapeutic potential. Validated target pathway; novel mode of pharmacological modulation.

Our story

Modern innovation based on a combined 40+ years of industry experience in Drug Discovery technologies and their incisive application to therapeutic R&D program advancement set the stage.

Broad Platform IP was incubated within Gold Mountain Research, LLC, with key insights from our New York City and Pittsburgh-based founding team.

Simply put, an Achilles’ Heel was discovered using advanced biophysical techniques and years of experience in searching for the hidden possibilities in protein-protein complex functional modulation.

Our unwavering commitment to crafting unique molecules driven by a cohesive and exquisitely experienced core team gives us a powerful advantage.

Several families of molecules are being advanced in the research pipeline.

Research and Business plans guide our pursuit for deploying capital to optimize our IP protected asset families into multiple Development Candidates. These will provide the strongest basis for differentiated orally-bioavailable medicines capable of alleviating multiple prominent diseases of immune dis-regulation.